{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T13:29:06Z","timestamp":1649683746833},"reference-count":0,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch med Wochenschr"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hypertension is defined as resistant to treatment when treatment fails to lower office systolic and diastolic blood pressure values to &lt;\u200a140\/90\u200ammHg. The treatment strategy should include lifestyle measures and appropriate doses of three or more drugs acting by different mechanisms including a diuretic. An updated definition of treatment resistance includes all patients with \u2265\u200a4 antihypertensive agents of different classes irrespective of their on-treatment blood pressure. The term \u201crefractory\u201d hypertension has been suggested for patients with uncontrolled blood pressure on \u2265\u200a5 antihypertensive drugs including the thiazide-like diuretic chlorthalidone and the mineralocorticoid receptor antagonist spironolactone. \u201cPseudo resistance\u201d especially due to white coat hypertension and non-adherence with the prescribed medication has to be ruled out to be able to identify patients with \u201ctrue\u201d treatment resistance. Therefore, before distinguishing true from pseudo resistance, the term \u201capparent\u201d resistance should be used. While the prevalence of apparent resistance may be in the range of 10\u201315\u200a% of treated patients, the exact prevalence of true resistance remains unknown due to the lack of appropriate studies but is likely to be rather small including a high proportion of patients with secondary forms of hypertension. Once identified most patients with true treatment resistance should receive intensified drug treatment primarily by expanded diuretic usage. Thus, resistant hypertension is primarily a diagnostic challenge: identifying patients with true resistance and those with secondary hypertension.<\/jats:p>","DOI":"10.1055\/a-1031-0612","type":"journal-article","created":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T18:34:06Z","timestamp":1579545246000},"page":"87-91","source":"Crossref","is-referenced-by-count":1,"title":["Therapieresistente und \u2011refrakt\u00e4re Hypertonie"],"prefix":"10.1055","volume":"145","author":[{"given":"Rainer","family":"D\u00fcsing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2020,1,20]]},"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1031-0612.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T18:34:15Z","timestamp":1579545255000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1031-0612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":0,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2020,1,20]]},"published-print":{"date-parts":[[2020,1]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1031-0612","relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]}}}